Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)

Ho, Jonathan; McNish, Alicia; McDonald, Letisha; Burrell, Carol; Smith-Matthews, Stephanie

doi:10.1016/j.jdcr.2022.05.002

Cited by 6 publications

(9 citation statements)

References 9 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In eight cases, AA appeared after the first dose, and four of them displayed aggravation of AA following the second dose. Their precise clinical outcomes were not documented, except for one case showing areas of sparse regrowth, 6 Our case displayed recovery of hair growth with topical corticosteroid therapy, suggesting that some cases of COVID‐19 vaccine‐related AA might recover without aggressive treatment.…”

Section: Figurementioning

confidence: 82%

See 1 more Smart Citation

A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome

Matsuda

Kawakami

Kawamoto

et al. 2023

J Cutaneous Imm & Allergy

View full text Add to dashboard Cite

show abstract

Section: Figurementioning

confidence: 82%

“…A review of the literature including the present case identified 17 cases of AA associated with COVID‐19 vaccines 2–7 . Six cases had a previous history of AA.…”

Section: Figurementioning

confidence: 92%

A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome

Matsuda

Kawakami

Kawamoto

et al. 2023

J Cutaneous Imm & Allergy

View full text Add to dashboard Cite

show abstract

“…108 Alopecia areata has been reported following COVID-19 vaccination. [109][110][111][112][113][114][115][116][117][118][119] The largest study on 77 patients developing alopecia areata (39) or a worsening of the disease (38) has been reported by Nguyen et al Unfortunately, it is not possible to correlate alopecia areata development and the type of vaccine. 120 Regarding bullous disorders, a total of 26 cased of pemphigus vulgaris have been reported following COVID-19 vaccination, [121][122][123][124][125][126][127][128][129][130][131][132][133][134][135] with several implications in treatment and management.…”

Section: Resultsmentioning

confidence: 99%

“… BNT162b2: 2 mRNA-1273: 3 AZD1222: 1 Ad26.COV2: 0 Urticaria 98 Magen et al 94 (39), Potestio et al 95 (15), Rerknimitr et al 77 (12), Riad et al 96 (10), Sidlow et al 97 (3), Peigottu et al 98 (2), Niebel et al 83 (2), McMahon et al 99 (2), Holmes et al 78 (2), Fernandez-Nieto et al 100 (2), Bianchi et al 101 (2), Corbeddu et al 102 (2), Baraldi et al 103 (1), Choi et al 104 (1), Patruno et al 105 (1), Burlando et al 106 (1), Thomas et al 107 (1). BNT162b2: 71 mRNA-1273: 12 AZD1222: 15 Ad26.COV2: 0 Alopecia areata 24 Scollan et al 109 (9), Babadjouni et al 110 (3), Rossi et al 111 (3), Chen et al 112 (2), Abdalla et al 113 (1), Gamonal et al 114 (1), Ho et al 115 (1), Su et al 116 (1), Gallo et al 117 (1), May Lee et al 118 (1), Essam et al 119 (1). BNT162b2: 14 mRNA-1273: 4 AZD1222: 6 Ad26.COV2: 0 Pemphigus vulgaris 26 Martora et al 121 (7), Zou et al 122 (3), Gui et al 123 (2), Rouatbi et al 124 (2), Aryanian et al 125 (1), Koutlas et al 126 (1), Knechtl et al 127 (1), Ong et al 128 (1), Yıldırıcı et al …”

Section: Methodsmentioning

confidence: 99%

“…Potestio et al95 (15), Rerknimitr et al77 (12), Riad et al96 (10), Sidlow et al97 (3), Peigottu et al98 (2), Niebel et al83 (2), McMahon et al99 (2), Holmes et al78 (2), Fernandez-Nieto et al100 (2), Bianchi et al101 (2), Corbeddu et al102 (2), Baraldi et al103 (1), Choi et al104 (1), Patruno et al105 (1), Burlando et al106 (1), Thomas et al107 (1) 109 (9),. Babadjouni et al110 (3), Rossi et al111 (3), Chen et al112 (2), Abdalla et al113 (1), Gamonal et al114 (1), Ho et al115 (1), Su et al116 (1), Gallo et al117 (1), May Lee et al118 (1), Essam et al 119 (1). Clinical, Cosmetic and Investigational Dermatology 2022:15 https://doi.org/10.2147/CCID.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

show abstract

Alopecia areata following COVID-19 vaccine: a systematic review

Zhu,

Ouyang,

Zhang

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

Background To date, multiple cases of adverse reactions to COVID-19 vaccines have been reported worldwide. Alopecia areata (AA) is an uncommon type of adverse reaction reported in some articles and has a significant social and psychological impact on patients. Our study aimed to review the AA and COVID-19 vaccine literature. Methods This systematic review was conducted by searching for articles on AA following COVID-19 vaccines in international databases such as Embase, MEDLINE, PubMed, Web of Knowledge, and Ovid from December 2019 to December 30, 2023. We included studies that provided data for AA patients following COVID-19 vaccination with at least one dose. Data on sex, age, country/region of origin, vaccine type, days between vaccination and symptom presentation, manifestations of AA, trichoscopy and histopathological findings, treatment, and outcomes were included. Results In total, 579 explored studies were identified and assessed, and 25 articles with a total of 51 patients were included in the review. Twenty-seven (52.9%) patients developed new-onset AA following receiving the COVID-19 vaccine, and AA recurrence or exacerbation occurred after receiving the COVID-19 vaccine in 24 (47.1%) patients with preexisting disease. Five vaccines were reported to cause AA in all cases. The Pfizer vaccine (45.1%) was the most frequently reported, followed by the ChAdOx1 nCoV-19 vaccine (27.5%), Moderna mRNA-1273 (19.6%), Sinopharm (3.9%) and SinoVac (3.9%). AA occurred most frequently within one month after the 1st dose, and then, the incidence decreased gradually with time. Topical or systemic corticosteroids were used in 38 patients. Eleven patients were treated with a Janus Kinase inhibitor (jakinib) inhibitor, eight with tofacitinib, and three with an unspecified jakinib. However, 3 of the 11 patients experienced exacerbations after treatment. Conclusion AA after COVID-19 vaccination is rare, and physicians should be aware of this phenomenon to improve early diagnosis and appropriate treatment.

show abstract

Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)

Cited by 6 publications

References 9 publications

A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome

A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Alopecia areata following COVID-19 vaccine: a systematic review

Contact Info

Product

Resources

About